ARDS vs. REVB, ARAV, CWBR, BPTS, NBY, BPTSY, MBIO, VRPX, PHIO, and AGRX
Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Revelation Biosciences (REVB), Aravive (ARAV), CohBar (CWBR), Biophytis (BPTS), NovaBay Pharmaceuticals (NBY), Biophytis (BPTSY), Mustang Bio (MBIO), Virpax Pharmaceuticals (VRPX), Phio Pharmaceuticals (PHIO), and Agile Therapeutics (AGRX). These companies are all part of the "pharmaceutical preparations" industry.
Aridis Pharmaceuticals (NASDAQ:ARDS) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.
9.7% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Aridis Pharmaceuticals presently has a consensus price target of $2.00, indicating a potential upside of 3,215.65%. Given Aridis Pharmaceuticals' higher probable upside, equities analysts plainly believe Aridis Pharmaceuticals is more favorable than Revelation Biosciences.
Aridis Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.
In the previous week, Revelation Biosciences had 4 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 4 mentions for Revelation Biosciences and 0 mentions for Aridis Pharmaceuticals. Revelation Biosciences' average media sentiment score of 0.75 beat Aridis Pharmaceuticals' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the news media.
Aridis Pharmaceuticals received 92 more outperform votes than Revelation Biosciences when rated by MarketBeat users. However, 63.83% of users gave Revelation Biosciences an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
Revelation Biosciences has lower revenue, but higher earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.
Revelation Biosciences has a net margin of 0.00% compared to Aridis Pharmaceuticals' net margin of -5.11%. Aridis Pharmaceuticals' return on equity of 0.00% beat Revelation Biosciences' return on equity.
Summary
Aridis Pharmaceuticals beats Revelation Biosciences on 9 of the 16 factors compared between the two stocks.
Get Aridis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aridis Pharmaceuticals Competitors List
Related Companies and Tools
